Post Market Usability Evaluation Of The PicoSure Pro Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-21

Study Completion Date

2023-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat additional patients with the new PicoSure Pro device and collect additional data on the devices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos

NCT02103153

Unwanted Tattoos

COMPLETED NA

Prospective Clinical Study to Assess Safety and to Collect Data on Radiofrequency Microneedling Device(s) For the Purpose of Evaluating Treatment on Skin

NCT06023303

Dermatologic Conditions

COMPLETED NA

Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction

NCT02600104

Unwanted Wrinkles

UNKNOWN NA

Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device

NCT05096247

Wrinkle Benign Pigmented Lesions Benign Vascular Lesions

COMPLETED NA

Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos

NCT02110121

Unwanted Tattoos

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects are to be enrolled in this clinical study if they are a healthy male or female 18 years of age or older. Up to 100 subjects will be enrolled at up to 4 study centers. Subjects will be enrolled into one of the 3 groups; Group A, Group B, or Group C.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wrinkle Acne Scars Benign Epidermal Pigmented Lesions Benign Dermal Pigmented Lesions Tattoo Removal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Randomization is not used for determining which arm subjects will participate in, however, it will be used to determine which side of the treatment area will receive which treatment regimen (if in a group receiving split-face treatments).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: Split-Face Device Only Treatment

Subjects will receive a split face treatment with the PicoSure Pro and/or PicoSure devices using different device settings on each half of the face.

Group Type EXPERIMENTAL

PicoSure Pro Device

Intervention Type DEVICE

This device will be used for up to 4 treatments over the designated areas.

PicoSure Device

Intervention Type DEVICE

This device will be used for up to 4 treatments over the designated areas.

Group B: Split-Face Treatment with Cosmeceuticals

Subjects will receive a full face treatment with the PicoSure Pro or PicoSure device and will use topical cosmeceuticals on only half of their face.

Group Type EXPERIMENTAL

PicoSure Pro Device

Intervention Type DEVICE

This device will be used for up to 4 treatments over the designated areas.

PicoSure Device

Intervention Type DEVICE

This device will be used for up to 4 treatments over the designated areas.

Topical Cosmeceuticals

Intervention Type DRUG

Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.

Group C: Device Only Treatment

Subjects will receive treatments with the PicoSure Pro or PicoSure device on multiple areas of the body such as the face, décolletage, back, legs, arms, and hands.

Group Type EXPERIMENTAL

PicoSure Pro Device

Intervention Type DEVICE

This device will be used for up to 4 treatments over the designated areas.

PicoSure Device

Intervention Type DEVICE

This device will be used for up to 4 treatments over the designated areas.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PicoSure Pro Device

This device will be used for up to 4 treatments over the designated areas.

Intervention Type DEVICE

PicoSure Device

This device will be used for up to 4 treatments over the designated areas.

Intervention Type DEVICE

Topical Cosmeceuticals

Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A healthy male or female 18 years of age or older.
* Willing to undergo treatments with the PicoSure and PicoPro devices for pigmentary lesions, acne scars, skin revitalization, or tattoo removal.
* Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
* Understands and accepts the obligation and is logistically able to be present for all visits.
* Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion Criteria

* Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
* The subject is hypersensitive to light in the near infrared wavelength region.
* The subject takes medication which is known to increase sensitivity to sunlight.
* The subject has seizure disorders triggered by light.
* The subject takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
* The subject has an active localized or systemic infection, or an open wound in area being treated.
* The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated.
* The subject has common acquired nevi that are predisposed to the development of malignant melanoma.
* The subject has herpes simplex in the area being treated.
* The subject is receiving or has received gold therapy.
* The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study.
* The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Cautionary Criteria:

* Has unprotected sun exposure within four weeks of treatment, including the use of tanning beds or tanning products, such as creams, lotions and sprays may interfere with the laser treatment; Investigator discretion is required to determine feasibility of treatment administration.
* Has a coagulation disorder or is currently using anti-coagulation medications. Anticoagulants may cause excessive bleeding and interfere with posttreatment healing; Investigator discretion is required to determine feasibility of treatment administration for subjects taking anticoagulants.
* Is taking medications that alter the wound-healing response which may interfere with posttreatment healing and may require special precautions to be taken by a treating Investigator.
* Is known to have a history of healing problems or history of keloid formation, Investigator discretion is required to determine the feasibility of treatment administration.
* Has a history of skin cancer or suspicious lesions, Investigator discretion is required to determine feasibility of treatment administration.
* Has had a chemical or mechanical epilation within the last six weeks may interfere with the post treatment healing process; Investigator discretion is required to determine feasibility of treatment administration.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No